BACKGROUND: Nanotechnology-based drug delivery approaches may help increase therapeutic efficacy and decrease side effects of chemotherapeutics. We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy. METHODS: Folate receptor expression levels in archival SCCHN tissues were analyzed by immunohistochemistry and correlated with clinical parameters. RESULTS: Folate receptor was detected in 45% of primary tumors and 40% of corresponding lymph node metastases. Folate receptor expression in primary tumors of the metastatic group strongly correlated with the corresponding lymph node metastases (p = .0002). Folate receptor expression was inversely correlated with disease-free survival in nonmetastatic (p = .0048), metastatic (p = .0127), and lymph node metastases (p <.001) groups, and with overall survival in the lymph node metastases group (p <.0001). CONCLUSION: Folate receptor is expressed in a significant proportion of primary SCCHN and corresponding lymph node metastases tissues, and correlates with worse clinical outcome. These findings provide support for folate receptor-mediated nanotherapeutics in SCCHN.
BACKGROUND: Nanotechnology-based drug delivery approaches may help increase therapeutic efficacy and decrease side effects of chemotherapeutics. We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy. METHODS:Folate receptor expression levels in archival SCCHN tissues were analyzed by immunohistochemistry and correlated with clinical parameters. RESULTS:Folate receptor was detected in 45% of primary tumors and 40% of corresponding lymph node metastases. Folate receptor expression in primary tumors of the metastatic group strongly correlated with the corresponding lymph node metastases (p = .0002). Folate receptor expression was inversely correlated with disease-free survival in nonmetastatic (p = .0048), metastatic (p = .0127), and lymph node metastases (p <.001) groups, and with overall survival in the lymph node metastases group (p <.0001). CONCLUSION:Folate receptor is expressed in a significant proportion of primary SCCHN and corresponding lymph node metastases tissues, and correlates with worse clinical outcome. These findings provide support for folate receptor-mediated nanotherapeutics in SCCHN.
Authors: Jinru Shia; David S Klimstra; James R Nitzkorski; Philip S Low; Mithat Gonen; Ron Landmann; Martin R Weiser; Wilbur A Franklin; Franklyn G Prendergast; Linda Murphy; Laura H Tang; Larissa Temple; Jose G Guillem; W Douglas Wong; Philip B Paty Journal: Hum Pathol Date: 2008-04 Impact factor: 3.466
Authors: Christopher P Leamon; Matthew A Parker; Iontcho R Vlahov; Le-Cun Xu; Joseph A Reddy; Marilynn Vetzel; Nikki Douglas Journal: Bioconjug Chem Date: 2002 Nov-Dec Impact factor: 4.774
Authors: Mohiuddin A Quadir; Stephen W Morton; Lawrence B Mensah; Kevin Shopsowitz; Jeroen Dobbelaar; Nicole Effenberger; Paula T Hammond Journal: Nanomedicine Date: 2017-03-02 Impact factor: 5.307
Authors: Michael E Werner; Jonathan A Copp; Shrirang Karve; Natalie D Cummings; Rohit Sukumar; Chenxi Li; Mary E Napier; Ronald C Chen; Adrienne D Cox; Andrew Z Wang Journal: ACS Nano Date: 2011-10-28 Impact factor: 15.881
Authors: Joel Y Sun; Jiayin Shen; Joel Thibodeaux; Gang Huang; Yiguang Wang; Jinming Gao; Philip S Low; Dimiter S Dimitrov; Baran D Sumer Journal: Laryngoscope Date: 2014-03-04 Impact factor: 3.325